COSCIENS Biopharma (CSCI) Competitors $4.23 +0.13 (+3.17%) (As of 09/18/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends CSCI vs. LUMO, EQ, SHPH, DARE, VYNE, EYEN, CUE, LPCN, GANX, and AEONShould you be buying COSCIENS Biopharma stock or one of its competitors? The main competitors of COSCIENS Biopharma include Lumos Pharma (LUMO), Equillium (EQ), Shuttle Pharmaceuticals (SHPH), Daré Bioscience (DARE), VYNE Therapeutics (VYNE), Eyenovia (EYEN), Cue Biopharma (CUE), Lipocine (LPCN), Gain Therapeutics (GANX), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry. COSCIENS Biopharma vs. Lumos Pharma Equillium Shuttle Pharmaceuticals Daré Bioscience VYNE Therapeutics Eyenovia Cue Biopharma Lipocine Gain Therapeutics AEON Biopharma Lumos Pharma (NASDAQ:LUMO) and COSCIENS Biopharma (NASDAQ:CSCI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations, profitability and community ranking. Do analysts recommend LUMO or CSCI? Lumos Pharma presently has a consensus target price of $20.50, suggesting a potential upside of 454.05%. Given Lumos Pharma's higher probable upside, research analysts plainly believe Lumos Pharma is more favorable than COSCIENS Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lumos Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00COSCIENS Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Do insiders & institutionals have more ownership in LUMO or CSCI? 34.0% of Lumos Pharma shares are owned by institutional investors. 25.4% of Lumos Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in LUMO or CSCI? Lumos Pharma received 35 more outperform votes than COSCIENS Biopharma when rated by MarketBeat users. CompanyUnderperformOutperformLumos PharmaOutperform Votes3577.78% Underperform Votes1022.22% COSCIENS BiopharmaN/AN/A Does the media refer more to LUMO or CSCI? In the previous week, Lumos Pharma had 1 more articles in the media than COSCIENS Biopharma. MarketBeat recorded 1 mentions for Lumos Pharma and 0 mentions for COSCIENS Biopharma. COSCIENS Biopharma's average media sentiment score of 1.89 beat Lumos Pharma's score of 1.44 indicating that COSCIENS Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Lumos Pharma Positive COSCIENS Biopharma Very Positive Is LUMO or CSCI more profitable? COSCIENS Biopharma has a net margin of -687.79% compared to Lumos Pharma's net margin of -2,405.72%. COSCIENS Biopharma's return on equity of -81.05% beat Lumos Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lumos Pharma-2,405.72% -157.99% -103.75% COSCIENS Biopharma -687.79%-81.05%-42.03% Which has preferable earnings & valuation, LUMO or CSCI? COSCIENS Biopharma has higher revenue and earnings than Lumos Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLumos Pharma$1.49M20.21-$34.03M-$4.59-0.81COSCIENS Biopharma$7.68M0.99-$16.55MN/AN/A Which has more volatility and risk, LUMO or CSCI? Lumos Pharma has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500. Comparatively, COSCIENS Biopharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. SummaryLumos Pharma and COSCIENS Biopharma tied by winning 7 of the 14 factors compared between the two stocks. Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. Get COSCIENS Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CSCI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSCI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSCI vs. The Competition Export to ExcelMetricCOSCIENS BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.57M$7.86B$5.67B$8.25BDividend YieldN/A4.33%4.99%4.07%P/E RatioN/A19.61140.3218.67Price / Sales0.99238.851,617.6870.68Price / CashN/A37.1137.2131.82Price / Book0.285.874.824.52Net Income-$16.55M$151.12M$115.60M$224.71M7 Day Performance3.17%4.05%3.72%4.97%1 Month PerformanceN/A12.35%8.86%8.36%1 Year PerformanceN/A21.73%28.72%11.79% COSCIENS Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LUMOLumos Pharma3.2414 of 5 stars3.24 / 5 stars$3.70-4.6%$20.50+454.1%+19.8%$30.03M$1.49M-0.8130Positive NewsEQEquillium2.5872 of 5 stars2.59 / 5 stars$0.85-1.2%$5.00+488.2%+3.0%$29.97M$42.62M-2.3640News CoverageGap UpSHPHShuttle Pharmaceuticals1.994 of 5 stars1.99 / 5 stars$1.66-3.5%N/AN/A$27.88MN/A-3.615Gap DownDAREDaré Bioscience1.6698 of 5 stars1.67 / 5 stars$3.23-0.3%$54.00+1,571.8%-47.1%$27.20M$2.84M-0.8430Short Interest ↑News CoverageVYNEVYNE Therapeutics3.4302 of 5 stars3.43 / 5 stars$1.86+1.6%$5.75+209.1%-52.5%$27.02M$486,000.00-0.3430Short Interest ↓EYENEyenovia3.4195 of 5 stars3.42 / 5 stars$0.50-2.0%$10.00+1,900.0%-70.8%$26.94M$31,405.00-0.6740CUECue Biopharma4.3432 of 5 stars4.34 / 5 stars$0.55-3.5%$5.00+803.0%-77.7%$26.93M$8.30M-0.5260Short Interest ↓LPCNLipocine0.6386 of 5 stars0.64 / 5 stars$5.01+3.7%N/A+32.7%$26.79M$4.80M-2.9310Positive NewsGANXGain Therapeutics3.0703 of 5 stars3.07 / 5 stars$1.48-1.3%$7.33+395.5%-59.6%$26.72M$50,000.00-0.9920Gap DownAEONAEON Biopharma1.4001 of 5 stars1.40 / 5 stars$0.67-4.3%$5.00+646.3%-87.6%$26.21MN/A0.005 Related Companies and Tools Related Companies: LUMO Competitors EQ Competitors SHPH Competitors DARE Competitors VYNE Competitors EYEN Competitors CUE Competitors LPCN Competitors GANX Competitors AEON Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CSCI) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COSCIENS Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share COSCIENS Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
